Zolmitriptan

Zolmitriptan

Clinical data
Trade names	Zomig, others
AHFS/Drugs.com	Monograph
MedlinePlus	a601129
License data	US DailyMed: Zolmitriptan
Pregnancy category	AU: B3
Routes of administration	By mouth, nasal spray
ATC code	N02CC03 (WHO)
Legal status
Legal status	CA: ℞-only[1] US: ℞-only
Pharmacokinetic data
Bioavailability	40% (oral)
Protein binding	25%
Metabolism	Liver (CYP1A2-mediated, to active metabolite)
Elimination half-life	3 hours
Excretion	Kidney (65%) and fecal (35%)
Identifiers
IUPAC name (S)-4-({3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one
CAS Number	139264-17-8 Y
PubChem CID	60857
IUPHAR/BPS	60
DrugBank	DB00315 Y
ChemSpider	54844 Y
UNII	2FS66TH3YW
KEGG	D00415 Y
ChEBI	CHEBI:10124 Y
ChEMBL	ChEMBL1185 Y
CompTox Dashboard (EPA)	DTXSID8045933
ECHA InfoCard	100.158.186
Chemical and physical data
Formula	C16H21N3O2
Molar mass	287.363 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1OC[C@@H](N1)Cc2ccc3c(c2)c(c[nH]3)CCN(C)C
InChI InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1 Y Key:ULSDMUVEXKOYBU-ZDUSSCGKSA-N Y
(verify)

Zolmitriptan, sold under the brand name Zomig among others, is a triptan used in the acute treatment of migraine attacks with or without aura and cluster headaches. It is a selective serotonin receptor agonist of the 1B and 1D subtypes.

It was patented in 1990 and approved for medical use in 1997.^[2]